These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

359 related items for PubMed ID: 21502541

  • 1. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia.
    Bussel JB, Buchanan GR, Nugent DJ, Gnarra DJ, Bomgaars LR, Blanchette VS, Wang YM, Nie K, Jun S.
    Blood; 2011 Jul 07; 118(1):28-36. PubMed ID: 21502541
    [Abstract] [Full Text] [Related]

  • 2. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).
    Bussel JB, Hsieh L, Buchanan GR, Stine K, Kalpatthi R, Gnarra DJ, Ho RH, Nie K, Eisen M.
    Pediatr Blood Cancer; 2015 Feb 07; 62(2):208-213. PubMed ID: 25345874
    [Abstract] [Full Text] [Related]

  • 3. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.
    Tarantino MD, Bussel JB, Blanchette VS, Despotovic J, Bennett C, Raj A, Williams B, Beam D, Morales J, Rose MJ, Carpenter N, Nie K, Eisen M.
    Lancet; 2016 Jul 02; 388(10039):45-54. PubMed ID: 27103127
    [Abstract] [Full Text] [Related]

  • 4. Romiplostim: a review of its use in immune thrombocytopenia.
    Keating GM.
    Drugs; 2012 Feb 12; 72(3):415-35. PubMed ID: 22316355
    [Abstract] [Full Text] [Related]

  • 5. Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial.
    Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Okamoto S, Kurokawa M, Kirito K, Yonemura Y, Mori S, Usuki K, Iwato K, Hashino S, Wei H, Lizambri R.
    Int J Hematol; 2011 Jul 12; 94(1):71-80. PubMed ID: 21706145
    [Abstract] [Full Text] [Related]

  • 6. Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia.
    Tarantino MD, Bussel JB, Blanchette VS, Beam D, Roy J, Despotovic J, Raj A, Carpenter N, Mehta B, Eisen M.
    Haematologica; 2019 Nov 12; 104(11):2283-2291. PubMed ID: 30846500
    [Abstract] [Full Text] [Related]

  • 7. An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP).
    Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Iwato K, Okamoto S, Kurokawa M, Kirito K, Hashino S, Ninomiya H, Mori S, Yonemura Y, Usuki K, Wei H, Lizambri R.
    Int J Hematol; 2012 Jun 12; 95(6):652-9. PubMed ID: 22532046
    [Abstract] [Full Text] [Related]

  • 8. Romiplostim in chronic immune thrombocytopenic purpura.
    Cersosimo RJ.
    Clin Ther; 2009 Sep 12; 31(9):1887-907. PubMed ID: 19843480
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥ 65 years with immune thrombocytopenia.
    Michel M, Wasser J, Godeau B, Aledort L, Cooper N, Tomiyama Y, Khellaf M, Wang X.
    Ann Hematol; 2015 Dec 12; 94(12):1973-80. PubMed ID: 26341755
    [Abstract] [Full Text] [Related]

  • 10. Romiplostim therapy in children with unresponsive chronic immune thrombocytopenia.
    Mokhtar GM, Tantawy AA, El Sherif NH.
    Platelets; 2012 Dec 12; 23(4):264-73. PubMed ID: 22471399
    [Abstract] [Full Text] [Related]

  • 11. Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice.
    Neunert CE, Rose MJ.
    Blood Adv; 2019 Jun 25; 3(12):1907-1915. PubMed ID: 31239245
    [Abstract] [Full Text] [Related]

  • 12. Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim.
    Cines DB, Gernsheimer T, Wasser J, Godeau B, Provan D, Lyons R, Altomare I, Wang X, Lopez A.
    Int J Hematol; 2015 Sep 25; 102(3):259-70. PubMed ID: 26201709
    [Abstract] [Full Text] [Related]

  • 13. Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials.
    Rodeghiero F, Stasi R, Giagounidis A, Viallard JF, Godeau B, Pabinger I, Cines D, Liebman H, Wang X, Woodard P.
    Eur J Haematol; 2013 Nov 25; 91(5):423-36. PubMed ID: 23927437
    [Abstract] [Full Text] [Related]

  • 14. A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia.
    Grainger J, Bussel J, Tarantino M, Cooper N, Beam D, Despotovic J, Maschan A, Wang K, Eisen M, Bowers C.
    Blood Adv; 2023 Feb 14; 7(3):396-405. PubMed ID: 35413092
    [Abstract] [Full Text] [Related]

  • 15. A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura.
    Shirasugi Y, Ando K, Hashino S, Nagasawa T, Kurata Y, Kishimoto Y, Iwato K, Ohtsu T, Berger DP.
    Int J Hematol; 2009 Sep 14; 90(2):157-165. PubMed ID: 19543952
    [Abstract] [Full Text] [Related]

  • 16. Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials.
    Tarantino MD, Despotovic J, Roy J, Grainger J, Cooper N, Beam D, Raj A, Maschan A, Kim J, Eisen M.
    Pediatr Blood Cancer; 2020 Nov 14; 67(11):e28630. PubMed ID: 32902132
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial.
    Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, Liebman HA, Slovick FT, de Wolf JT, Bourgeois E, Guthrie TH, Newland A, Wasser JS, Hamburg SI, Grande C, Lefrère F, Lichtin AE, Tarantino MD, Terebelo HR, Viallard JF, Cuevas FJ, Go RS, Henry DH, Redner RL, Rice L, Schipperus MR, Guo DM, Nichol JL.
    Lancet; 2008 Feb 02; 371(9610):395-403. PubMed ID: 18242413
    [Abstract] [Full Text] [Related]

  • 18. Highly fluctuating thrombocytopenia developing in a patient with immune thrombocytopenia (ITP) while administering romiplostim.
    Shinohara K, Kambara N.
    Intern Med; 2012 Feb 02; 51(11):1399-401. PubMed ID: 22687850
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of self-administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trials.
    Kuter DJ, Arnold DM, Rodeghiero F, Janssens A, Selleslag D, Bird R, Newland A, Mayer J, Wang K, Olie R.
    Am J Hematol; 2020 Jun 02; 95(6):643-651. PubMed ID: 32129511
    [Abstract] [Full Text] [Related]

  • 20. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Effect of Romiplostim on Health-Related Quality of Life in Children with Primary Immune Thrombocytopenia and Associated Burden in Their Parents.
    Mathias SD, Li X, Eisen M, Carpenter N, Crosby RD, Blanchette VS.
    Pediatr Blood Cancer; 2016 Jul 02; 63(7):1232-7. PubMed ID: 27037553
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.